Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001435358 | SCV001638178 | likely benign | Mucopolysaccharidosis, MPS-IV-B; GM1 gangliosidosis | 2024-11-27 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV002261364 | SCV002542034 | uncertain significance | not provided | 2021-06-21 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002555195 | SCV003530806 | likely benign | Inborn genetic diseases | 2022-01-12 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |